Geert D'Haens
Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis.
D'Haens G, Dubinsky M, Kobayashi T, Irving P, Howaldt S, Pokrotnieks J, Krueger K, Laskowski J, Li X, Lissoos T, Milata J, Morris N, Arora V, Milch C, Sandborn W, Sands B, LUCENT Study Group, Brand S. Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med 2023; 388:2444-2455.
29.06.2023Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis.
29.06.2023N Engl J Med 2023; 388:2444-2455
D'Haens Geert, Dubinsky Marla, Kobayashi Taku, Irving Peter M, Howaldt Stefanie, Pokrotnieks Juris, Krueger Kathryn, Laskowski Janelle, Li Xingyuan, Lissoos Trevor, Milata Joe, Morris Nathan, Arora Vipin, Milch Catherine, Sandborn William J, Sands Bruce E, LUCENT Study Group, Brand Stephan
Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study.
Danese S, Colombel J, Lukas M, Gisbert J, D'Haens G, Hayee B, Panaccione R, Kim H, Reinisch W, Tyrrell H, Oh Y, Tole S, Chai A, Chamberlain-James K, Tang M, Schreiber S, GARDENIA Study Group. Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study. Lancet Gastroenterol Hepatol 2021; 7:118-127.
17.11.2021Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study.
17.11.2021Lancet Gastroenterol Hepatol 2021; 7:118-127
Danese Silvio, Colombel Jean-Frédéric, Lukas Milan, Gisbert Javier P, D'Haens Geert, Hayee Bu'hussain, Panaccione Remo, Kim Hyun-Soo, Reinisch Walter, Tyrrell Helen, Oh Young S, Tole Swati, Chai Akiko, Chamberlain-James Kirsten, Tang Meina Tao, Schreiber Stefan, GARDENIA Study Group